Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Crage Medical Co. Limited currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This indicates that the company's patent filings are being reviewed in different specialized environments at the patent office. The busiest examiner, DUFFY, BRADLEY, is assigned 1 busiest examiner pending office action.
Since there are 2 pending office actions and 2 distinct examiners, each examiner is handling exactly one case. The use of 2 distinct art units suggests that the company is navigating different sets of examination priorities or technical standards. For a practitioner, this variety means that the prosecution strategy must be adaptable to the different styles of 2 distinct examiners. The portfolio shows more structural diversity than those limited to a single art unit, even with a small number of active cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
| BELYAVSKYI, MICHAIL A | 1 | 64.2% | +27.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284961 | CELLULAR IMMUNOTHERAPY USE | DUFFY, BRADLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174565 | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY | BELYAVSKYI, MICHAIL A | 393d overdue |
| 18284961 | CELLULAR IMMUNOTHERAPY USE | DUFFY, BRADLEY | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18284961 | CELLULAR IMMUNOTHERAPY USE | DUFFY, BRADLEY | 1643 | §101§102§112DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18174565 | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 393d overdue | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial